Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 16:105:adv43419.
doi: 10.2340/actadv.v105.43419.

Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment

Yoshihito Mima  1 , Masako Yamamoto  2 , Ken Iozumi  2
Affiliations

Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment

Yoshihito Mima et al. Acta Derm Venereol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

YM and KI have received lecture fees from Maruho Co., which markets nemolizumab.

Figures

Fig. 1
Fig. 1
Clinical features of Patient 1 with prurigo nodularis who switched to nemolizumab after 12 weeks of dupilumab treatment due to persistent pruritus. (A) Baseline back lesions at the start of nemolizumab treatment. Before nemolizumab, dupilumab had led to partial flattening of the nodules, but numerous palpable lesions remained (PN-IGA 4), and pruritus remained severe (PP-NRS 7). (B) At Week 4, previously palpable nodules showed further flattening and signs of improvement (PN-IGA 3), though pruritus persisted (PP-NRS 5). (C) At Week 12, most nodules had flattened and evolved into post-inflammatory hyperpigmentation (PN-IGA 2), while pruritus remained stable (PP-NRS 6).
Fig. 2
Fig. 2
Clinical features of Patient 3 with prurigo nodularis who switched to nemolizumab after 13 weeks of dupilumab treatment due to persistent pruritus or skin lesions. (A) Baseline back lesions at the start of nemolizumab treatment. Before nemolizumab, despite prior dupilumab treatment, the nodules remained largely unchanged, with numerous palpable lesions (PN-IGA 4), and pruritus was extremely severe (PP-NRS 10). (B) At Week 4, the nodules showed no significant flattening and remained stable (PN-IGA 4), but pruritus improved markedly (PP-NRS 5). (C) At Week 12, some nodules showed signs of shrinkage, but many remained palpable (PN-IGA 4). However, pruritus continued to improve (PP-NRS 3).
See this image and copyright information in PMC

References

    1. Pereira MP, Steinke, S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32: 1059-1065. 10.1111/jdv.14570 - DOI - PubMed
    1. Leis M, Fleming P, Lynde CW. Prurigo nodularis: review and emerging treatments. Skin Therapy Lett 2021; 26: 5–8. - PubMed
    1. Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol 2020; 83: 1567–1575. 10.1016/j.jaad.2020.04.182 - DOI - PubMed
    1. Kwatra SG, Ständer S, Yosipovitch G, Kim BS, Levit NA, O’Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of Type 2 inflammation. J Invest Dermatol 2025; 145: 249–256. 10.1016/j.jid.2024.06.1276 - DOI - PubMed
    1. Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol 2018; 142: 1375–1390. 10.1016/j.jaci.2018.09.005 - DOI - PubMed

LinkOut - more resources